This educational supplement discusses updated treatment guidelines for bacterial vaginosis (BV) and reviews literature on the association of BV and the risk of sexually transmitted infections that supports the need for proper BV treatment, whether symptomatic or asymptomatic.
Download the supplement
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More